A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

计划入组 92 人 · 首次发布于 2024 年 5 月 20 日

The Role of NaV1.8 in Human Pain Models

计划入组 67 人 · 首次发布于 2026 年 4 月 6 日

Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8

计划入组 36 人 · 首次发布于 2023 年 7 月 7 日

Nav1.8 inhibitor(Grunenthal)

Nav1.8 Inhibitor 2j(Sichuan University)

Nav1.8(Quiver Bioscience)

Corvus Pharmaceuticals

United States

Kura Oncology

United States

Odyssey Therapeutics

Latigo Bio Doses First Participant in Phase 1 Trial of Non-Opioid Pain Drug LTG-305

Novel NaV1.8 Inhibitors Lead Wave of Non-Opioid Pain Treatments as Industry Tackles Opioid Crisis

Latigo Biotherapeutics Files for IPO as Non-Opioid Pain Drug LTG-001 Advances to Late-Stage Testing